Press release
Fragile X Syndrome Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Anavex (ANAVEX2-73/blarcamesine), Zynerba, Autifony, Marinus, Healx
Fragile X Syndrome Pipeline
"Fragile X Syndrome Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Fragile X Syndrome Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Fragile X Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Fragile X Syndrome Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fragile X Syndrome treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fragile X Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
DelveInsight's Report covers around 22+ products under different phases of clinical development like -
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage products (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Some of the key companies in the Fragile X Syndrome Market include:
• Zynerba Pharmaceuticals
• Tetra Therapeutics
• Autifony Therapeutics
• Prilenia Therapeutics
• Alcobra Ltd.
• Seaside Therapeutics, Inc.
• Marinus Pharmaceuticals
• Novartis Pharmaceuticals
• Neuren Pharmaceuticals
• Hoffmann-La Roche
• Healx
• Nova Mentis
• Lysogene
• Actinogen
• Prilenia Therapeutics
• Confluence Pharmaceuticals
• Sentinel Oncology
And many more
Fragile X Syndrome Drugs covered in the report include
• Zatolmilast: Tetra Discovery Partners
• Zygel: Zynerba Pharmaceuticals
• Pridopidine: Prilenia Therapeutics
And many others
Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Report Introduction
2. Executive Summary
3. Fragile X Syndrome Current Treatment Patterns
4. Fragile X Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Fragile X Syndrome Late Stage Products (Phase-III)
7. Fragile X Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fragile X Syndrome Discontinued Products
13. Fragile X Syndrome Product Profiles
14. Fragile X Syndrome Key Companies
15. Fragile X Syndrome Key Products
16. Dormant and Discontinued Products
17. Fragile X Syndrome Unmet Needs
18. Fragile X Syndrome Future Perspectives
19. Fragile X Syndrome Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fragile X Syndrome Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Anavex (ANAVEX2-73/blarcamesine), Zynerba, Autifony, Marinus, Healx here
News-ID: 2798640 • Views: …
More Releases from DelveInsight Business Research
Global Patient Engagement Solutions Market to reach USD 59,499.28 million by 203 …
According to DelveInsight's analysis, The growth of the patient engagement solutions market is primarily fueled by several major factors, including the increasing burden of chronic conditions such as diabetes and cardiovascular diseases, which require continuous patient involvement and monitoring. The industry is further propelled by the move toward patient-centric healthcare models, ongoing technological innovations, and the introduction of new digital tools and platforms. Moreover, supportive government policies and initiatives aimed…
Global Magnetic Resonance Imaging Devices Market to reach USD 13,553.33 million …
According to DelveInsight's analysis, The growing incidence of chronic illnesses-including heart disease, cancer, and neurological disorders is driving demand for advanced diagnostic methods such as MRI, which provides highly detailed imaging of soft tissues and internal organs. Increasing awareness and a stronger focus on early disease detection are also prompting both patients and healthcare professionals to rely on MRI for faster and more accurate diagnosis. In addition, ongoing technological progress…
Global Microbial Fermentation Technology Market Size was USD 33,956.10 million i …
According to DelveInsight's analysis, The microbial fermentation technology market is experiencing strong growth, largely due to the increasing incidence of chronic illnesses such as cancer and a range of infectious diseases, including HIV, hepatitis B and C, and influenza. The market is also being boosted by the rising need for advanced therapeutic products like cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies. Moreover, progress in synthetic biology and precision…
Global Surgical Robotic System Market to reach USD 29,785.13 million by 2032 at …
According to DelveInsight's analysis, The growing prevalence of chronic illnesses such as cancer, cardiovascular diseases, and orthopedic disorders is driving demand for advanced surgical solutions, which in turn is accelerating the expansion of the surgical robotic systems market. Since many of these conditions require complex, highly precise procedures, robotic-assisted surgery is becoming a preferred option due to its superior precision, less invasive nature, and faster patient recovery. At the same…
More Releases for Fragile
Fragile Yet Fearless: A Memoir That Demands to Be Read
In Fragile Strength, author Phyllis Ann opens the door to her life with extraordinary honesty and vulnerability, sharing a story that is both deeply personal and profoundly universal. With an unfiltered voice and powerful prose, she recounts her journey through trauma, mental illness, and survival, proving that even the most fragile beginnings can lead to a life of undeniable strength.
Raised in poverty, shaped by systemic barriers, and scarred by traumatic…
Fragile X Syndrome Fxs Treatment Market Size, Share & Trends [2035]
The Fragile X Syndrome Market Is Set To Grow At An Estimated CAGR Of 8.4% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $2.6 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Fragile X Syndrome Fxs Treatment market goods. The market study excludes key regions that are…
Fragile X-Syndrome Therapeutics Market: Treatment Strategies and Emerging Therap …
The Summary of the Fragile X-Syndrome Market Report
The MMR offers a concise depiction of the "Fragile X-Syndrome Market" industry, delivering an in-depth analysis of the Fragile X-Syndrome market. It emphasizes standard subjects while tailoring data to suit specific requirements. This overview serves as a comprehensive guide for investors seeking insights into the current landscape of the Fragile X-Syndrome industry.
Fragile X-Syndrome Market Expansion
Fragile X-Syndrome Market size is expected to grow at…
Sparkling Wine market status most fragile speculative growth trends
A new statistical surveying study titled Sparkling Wine Market investigates a few critical features identified with Sparkling Wine Market covering industry condition, division examination, and focused scene. Down to earth ideas of the market are referenced in a straightforward and unassuming way in this report. A far-reaching and exhaustive essential investigation report features various actualities, for example, improvement factors, business upgrade systems, measurable development, monetary benefit or misfortune to support…
Life Sciences Software market status most fragile speculative growth trends
Detailed research added by Ample Market Research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Life Sciences Software market in the latest research report. The research study concisely dissects the Life Sciences Software and unearths valuable estimations pertaining to the profit projections, market size, sales capacity, and numerous other crucial parameters. Also, the Life Sciences Software Market report appraises the industry fragments…
Fragile X Syndrome-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome-Pipeline Review, H2 2018, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.
Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay…
